Endothelin and the ischaemic heart.

@article{Wainwright2005EndothelinAT,
  title={Endothelin and the ischaemic heart.},
  author={Cherry L. Wainwright and Christopher J McCabe and Kathleen A. Kane},
  journal={Current vascular pharmacology},
  year={2005},
  volume={3 4},
  pages={333-41}
}
Soon after its identification as a powerful vasoconstrictor peptide, endothelin (ET-1) was implicated as a detrimental agent involved in determining the outcome of myocardial ischaemia and reperfusion. Early experimental studies demonstrated that ET(A) selective and mixed ET(A)/ET(B) receptor antagonists can reduce infarct size and prevent ischaemia-induced ventricular arrhythmias in models of ischaemia/reperfusion, implying that ET-1 acts through the ET(A) receptor to contribute to injury and… CONTINUE READING